ResMed (RMD) Competitors $256.96 +1.08 (+0.42%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$256.86 -0.10 (-0.04%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. MEDP, EHC, HIMS, SYK, MDT, BDX, EW, IDXX, DXCM, and STEShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector. ResMed vs. Its Competitors Medpace Encompass Health Hims & Hers Health Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom STERIS ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Does the media refer more to RMD or MEDP? In the previous week, ResMed had 21 more articles in the media than Medpace. MarketBeat recorded 27 mentions for ResMed and 6 mentions for Medpace. ResMed's average media sentiment score of 1.37 beat Medpace's score of 0.70 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 21 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RMD or MEDP more profitable? ResMed has a net margin of 26.15% compared to Medpace's net margin of 19.31%. Medpace's return on equity of 54.36% beat ResMed's return on equity.Company Net Margins Return on Equity Return on Assets ResMed26.15% 25.67% 18.59% Medpace 19.31%54.36%20.81% Which has better valuation and earnings, RMD or MEDP? ResMed has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$4.69B8.04$1.02B$8.9128.84Medpace$2.11B4.38$404.39M$13.1024.54 Which has more volatility and risk, RMD or MEDP? ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Do analysts rate RMD or MEDP? ResMed presently has a consensus price target of $259.33, indicating a potential upside of 0.92%. Medpace has a consensus price target of $344.82, indicating a potential upside of 7.25%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.64Medpace 0 Sell rating(s) 11 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.21 Do insiders and institutionals hold more shares of RMD or MEDP? 55.0% of ResMed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryResMed beats Medpace on 10 of the 17 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$37.68B$10.52B$5.54B$20.72BDividend Yield0.83%2.07%5.24%3.71%P/E Ratio28.8416.4627.4328.09Price / Sales8.0429.54416.8738.30Price / Cash27.8522.9936.8922.53Price / Book7.763.668.034.58Net Income$1.02B$235.40M$3.18B$986.06M7 Day Performance0.76%2.15%2.88%2.79%1 Month Performance2.91%3.38%3.69%5.46%1 Year Performance31.90%-10.18%36.02%15.06% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.6335 of 5 stars$256.96+0.4%$259.33+0.9%+35.7%$37.68B$4.69B28.849,980News CoveragePositive NewsInsider TradeMEDPMedpace4.4579 of 5 stars$313.86+1.0%$344.82+9.9%-20.2%$9.02B$2.16B23.965,900EHCEncompass Health4.8479 of 5 stars$122.60+0.3%$127.00+3.6%+38.4%$12.36B$5.37B25.3340,000News CoveragePositive NewsEx-DividendHIMSHims & Hers Health2.2033 of 5 stars$49.94+1.1%$39.58-20.7%+133.8%$11.18B$1.48B72.381,637Trending NewsInsider TradeSYKStryker4.5817 of 5 stars$395.71+0.8%$427.30+8.0%+18.1%$151.04B$23.22B53.4753,000Positive NewsMDTMedtronic4.8973 of 5 stars$87.25+1.4%$97.87+12.2%+14.7%$111.90B$33.54B24.1095,000Positive NewsBDXBecton, Dickinson and Company4.8503 of 5 stars$172.31+0.8%$219.22+27.2%-23.0%$49.39B$20.18B32.8877,000Positive NewsEWEdwards Lifesciences4.3594 of 5 stars$78.34+0.2%$80.20+2.4%-15.7%$45.95B$5.52B11.1917,300Positive NewsIDXXIDEXX Laboratories3.862 of 5 stars$536.34+0.9%$546.00+1.8%+14.4%$43.13B$3.90B49.5710,800Positive NewsAnalyst ForecastDXCMDexCom4.9202 of 5 stars$87.29+1.1%$98.50+12.8%-25.4%$34.23B$4.03B65.147,600Positive NewsSTESTERIS4.9362 of 5 stars$240.03+0.5%$263.83+9.9%+9.3%$23.61B$5.46B38.7116,000Positive News Related Companies and Tools Related Companies Medpace Competitors Encompass Health Competitors Hims & Hers Health Competitors Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors DexCom Competitors STERIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
